Sustained Health-Related Quality of Life (HRQoL) Improvement in Newly Diagnosed Multiple Myeloma Patients Treated with Bortezomib/Melphalan/Prednisone Versus Melphalan/Prednisone: Results From the VISTA Trial. | Publicación